title: Improvement of renal function with selective thromboxane A2 synthetase inhibitor, DP-1904 in lupus nephritis.
authors.affiliation: Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Yoshida
authors.forename: H
authors.initials: H
authors.lastname: Kameda
authors.forename: A
authors.initials: A
authors.lastname: Masashi
authors.forename: M
authors.initials: M
authors.lastname: Homma
authors.forename: Y
authors.initials: Y
authors.lastname: Ikeda
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine; D000328:Adult; D018592:Cross-Over Studies; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007213:Indomethacin / Q000627:therapeutic use*; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000652:urine; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors
chemical_list: D004791:Enzyme Inhibitors; D007093:Imidazoles; D013764:Tetrahydronaphthalenes; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C056295:nafagrel; D013930:Thromboxane-A Synthase; D007213:Indomethacin